1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. HEXO Corp.
  6. Summary
    HEXO   CA4283043079

HEXO CORP.

(HEXO)
  Report
Delayed Toronto Stock Exchange  -  03:59 2022-06-30 pm EDT
0.2700 CAD   +3.85%
06/29Tilray Expands Portfolio of Medical Cannabis Products in the UK; Edges Up in US Pre-market Trading
MT
06/29TILRAY BRANDS BRIEF : Tilray Medical Expands Portfolio of Medical Cannabis Products in the UK
MT
06/22Tilray Brands Welcomes Govt of Luxembourg Delegation Visit to European Campus in Portugal
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
06/24/2022 06/27/2022 06/28/2022 06/29/2022 06/30/2022 Date
0.295(c) 0.295(c) 0.275(c) 0.26(c) 0.27(c) Last
1 385 663 770 719 1 110 899 1 268 144 1 355 835 Volume
+1.72% 0.00% -6.78% -5.45% +3.85% Change
More quotes
Estimated financial data (e)
Sales 2022 196 M 152 M 152 M
Net income 2022 -984 M -762 M -762 M
Net Debt 2022 168 M 130 M 130 M
P/E ratio 2022 -0,11x
Yield 2022 -
Sales 2023 209 M 162 M 162 M
Net income 2023 -51,9 M -40,2 M -40,2 M
Net Debt 2023 373 M 289 M 289 M
P/E ratio 2023 -3,52x
Yield 2023 -
Capitalization 135 M 105 M 105 M
EV / Sales 2022 1,55x
EV / Sales 2023 2,43x
Nbr of Employees -
Free-Float 97,3%
More Financials
Company
HEXO Corp. is a Canada-based consumer packaged goods cannabis company, which creates and distributes products for the cannabis market. The Company is engaged in cultivating, processing, packaging and distributing cannabis products. The Company serves Canadian adult-use market through its HEXO, HEXO Plus, Up, Bake Sale, Namaste, REUP and Original Stash brands, and the medical market through its HEXO brand. Its HEXO... 
Sector
Pharmaceuticals
Calendar
07/04 | 10:00amShareholder meeting
More about the company
Ratings of HEXO Corp.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about HEXO CORP.
06/29Tilray Expands Portfolio of Medical Cannabis Products in the UK; Edges Up in US Pre-mar..
MT
06/29TILRAY BRANDS BRIEF : Tilray Medical Expands Portfolio of Medical Cannabis Products in the..
MT
06/22Tilray Brands Welcomes Govt of Luxembourg Delegation Visit to European Campus in Portug..
MT
06/22TILRAY BRANDS BRIEF : Welcomes Government of Luxembourg Delegation Visit to European Campu..
MT
06/20Sundial Growers Enters into a Bid Agreement for HEXO Subsidiary Zenabis Global's Assets
MT
06/20SUNDIAL GROWERS INC. BRIEF : Refers To HEXO Corp.'s Publicly Filed Fiinancial Statements a..
MT
06/20SUNDIAL GROWERS INC. BRIEF : Enters into a Bid Agreement for Zenabis Global Inc.'s Assets
MT
06/20Sundial Growers Inc. entered into a purchase agreement to acquire Zenabis Global Inc. f..
CI
06/17Cannabis company Hexo's Zenabis subsidiary files for CCAA protection
AQ
06/17HEXO Says Subsidiary Zenabis Files for Creditor Protection; Edges Up in US Pre-market T..
MT
06/17HEXO BRIEF : Acknowledges Zenabis Group CCAA Filing
MT
06/17HEXO Acknowledges Zenabis Group CCAA Filing
GL
06/16HEXO : Press release dated June 15, 2022 - Form 6-K
PU
06/16Canaccord Genuity Downgrades HEXO to Hold From Speculative Buy, Adjusts Price Target to..
MT
06/16Tilray Brands Expands Premium Cannabis Brand Broken Coast's Portfolio
MT
More news
News in other languages on HEXO CORP.
06/15HEXO en baisse de 1% à son plus bas niveau sur 52 semaines dans le pré-marché américain..
06/14Piper Sandler sur Tilray Brands ; baisse des estimations sur un momentum plus faible
06/14HEXO conclut des conventions de modification touchant la convention relative à l'opérat..
06/14HEXO Corp. annonce ses résultats financiers pour le troisième trimestre et les neuf moi..
05/11HEXO déposera une circulaire d'information de la direction pour obtenir l'approbation d..
More news
Analyst Recommendations on HEXO CORP.
More recommendations
Chart HEXO CORP.
Duration : Period :
HEXO Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HEXO CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 9
Last Close Price 0,27 CAD
Average target price 0,29 CAD
Spread / Average Target 8,64%
EPS Revisions
Managers and Directors
Charles Bowman President & Chief Executive Officer
Julius Ivancsits Chief Financial Officer
Mark Attanasio Executive Chairman
Jackie Fletcher Vice President-Science & Technology
Vincent Chiara Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HEXO CORP.-69.32%105
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782